DaShenLin Pharmaceutical Group Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHG:603233
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 839 out of 851
Universe
Global Universe 14163 out of 15104
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
China Medical System Holdings Ltd. |
25.6
Medium
|
215 out of 851 |
The United Laboratories International Holdings Ltd. |
26.9
Medium
|
278 out of 851 |
Hanmi Pharmaceutical Co., Ltd. |
35.1
High
|
661 out of 851 |
China Meheco Group Co., Ltd. |
40.5
Severe
|
823 out of 851 |
DaShenLin Pharmaceutical Group Co., Ltd. |
42
Severe
|
839 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
DaShenLin Pharmaceutical Group Co., Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
DaShenLin Pharmaceutical Group Co., Ltd.'s Management of ESG Material Risk is Weak
How do the ESG Risk Ratings work?
Top Material ESG Issues for DaShenLin Pharmaceutical Group Co., Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted DaShenLin Pharmaceutical Group Co., Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level